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In the worlds of environmental health and
environmental medicine, lead exposure
remains one of the most important problems
in terms of prevalence of exposure and public
health impact. Despite decades of intensive
research, lead toxicity also remains one of the
most, if not the most, studied subjects of all
within the ﬁelds of environmental health and
environmental medicine. This reflects the
large gaps that continue to exist in our under-
standing of the full implications of lead expo-
sure on health: how lead exposure may
impact on chronic diseases; what mechanisms
dictate lead’s health effects; how to predict,
monitor, and manage lead toxicity; and what
factors may modify lead’s effects. 
Epidemiologic studies form the body of
research most relevant to anticipating human
health effects and developing guidelines for
preventing and managing human exposures.
In recent years, we have seen great advances in
their level of sophistication and design. Such
advances allow greater inference in terms of
issues critical to prevention and public health,
such as potential causality, dose–response rela-
tionships, and susceptible subpopulations. 
Two of the articles in this mini-mono-
graph are reviews of the effects of lead on the
cardiovascular system and upon cognitive
function in adults (Navas-Acien et al. 2007;
Shih et al. 2007). Issues of methodology
determine the conﬁdence to be placed on the
validity of the evidence presented in such
reviews and the strength of the appropriate
inferences. In this present article we attempt to
review and address the major methodologic
issues common across studies. Chief among
the recent developments in methodologic
advances has been the reﬁnement of concepts
and methods for measuring individual lead
dose. This includes appreciating distinctions
between recent versus cumulative doses and
acute versus chronic effects, as well as the use
of biological markers in epidemiologic studies
to measure these parameters. In this article, we
review this topic in some depth.
We also address important issues related
to epidemiologic design, such as cross-
sectional versus longitudinal studies; commu-
nity-based versus occupational studies; and
the identiﬁcation and control of bias and con-
founding. Our goal in this article is to provide
the methodologic basis to interpret the major
issues that are of relevance to the articles in the
mini-monograph as well as future studies
intending to investigate the effect of lead on
health outcomes. 
Measurement of Lead Dose
Concepts and overview. In reviewing studies
of the health effects of lead, it is critical to
understand the available lead biomarkers in
terms of how they represent external exposure
(in terms of timing, duration, magnitude, and
accumulation), how they are influenced by
metabolic factors (organ distribution, com-
partmental dynamics, the inﬂuence of physio-
logic factors), and how the combination of
these considerations impacts inferences
regarding the health effects of lead. In this
section, our goal is to persuade the reader that
the most informative recent epidemiologic
studies of the impact of lead on health are
those that were able to derive estimates of
both recent and cumulative lead dose for each
study participant. 
To achieve this end with greatest preci-
sion and accuracy, such studies have incorpo-
rated measurements of lead in both blood
(whole blood, using standard chemical assays
such as graphite furnace atomic absorption
spectroscopy) and bone (using noninvasive
in vivo K-shell X-ray fluorescence [KXRF]
instruments). Blood lead levels are an indica-
tor of circulating lead that captures variation
in recent external lead exposure as well as lead
that has been mobilized from tissue stores
(mostly bone). Lead levels in tibia and patella
provide an indication of cumulative dose over
decades (particularly cortical tissue in tibia) as
well as the largest pool of lead in the body
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We review several issues of broad relevance to the interpretation of epidemiologic evidence concern-
ing the toxicity of lead in adults, particularly regarding cognitive function and the cardiovascular
system, which are the subjects of two systematic reviews that are also part of this mini-monograph.
Chief among the recent developments in methodologic advances has been the reﬁnement of con-
cepts and methods for measuring individual lead dose in terms of appreciating distinctions between
recent versus cumulative doses and the use of biological markers to measure these parameters in
epidemiologic studies of chronic disease. Attention is focused particularly on bone lead levels meas-
ured by K-shell X-ray ﬂuorescence as a relatively new biological marker of cumulative dose that has
been used in many recent epidemiologic studies to generate insights into lead’s impact on cognition
and risk of hypertension, as well as the alternative method of estimating cumulative dose using
available repeated measures of blood lead to calculate an individual’s cumulative blood lead index.
We review the relevance and interpretation of these lead biomarkers in the context of the toxico-
kinetics of lead. In addition, we also discuss methodologic challenges that arise in studies of occupa-
tionally and environmentally exposed subjects and those concerning race/ethnicity and
socioeconomic status and other important covariates. Key words: adults, biomarkers, epidemiologic
methods, epidemiology, lead, toxicity. Environ Health Perspect 115:455–462 (2007).
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The latter phenomenon is heightened at
times of high bone resorption (e.g., during
pregnancy, aging, postmenopause). Taken
together, blood and bone lead levels have pro-
vided recent epidemiologic studies with the
best available assessment tools for estimating
both recent and cumulative lead. It is also
noted that an acceptable surrogate for cumu-
lative lead dose that does not require KXRF
measurement of lead in bone can be derived
by using repeated measures of blood lead over
time of exposure to derive time-integrated
indices such as working lifetime time-inte-
grated blood lead levels [IBL—the area under
the curve of blood lead vs. time, also termed
cumulative blood lead index (CBLI)]. Such
measures have been demonstrated to be well-
correlated with tibia lead levels (Roels et al.
1995; Somervaille et al. 1988), and this is
reviewed in detail below. However, epidemio-
logic studies (particularly of nonoccupational
cohorts) that have had access to valid mea-
sures of blood lead repeated over years of
exposure have been rare. 
Blood lead levels measured in epidemio-
logic studies with valid instruments and stan-
dardized calibration and quality control
procedures have been reported in the litera-
ture for more than 35 years. Bone lead levels
measured by in vivo KXRF were begun in
some research laboratories in the 1980s, but it
was not until the mid-1990s that reports
began to emerge of KXRF-measured bone
lead levels in relation to potential health indi-
cators from epidemiologic studies with large
enough sample sizes (e.g., 100 or more sub-
jects) to have substantial statistical power.
Below we discuss these issues in more detail. 
Issues of validity related to recent and
cumulative lead dose. When reviewing studies
on the health effects of an “exposure,” it is
critical to evaluate the validity of biological
tests (i.e., biomarkers) used to measure “expo-
sure.” Validity, in this context, incorporates
notions of measurement precision and accu-
racy as well as the value of the metric in pre-
dicting the health outcome(s) of interest. 
With respect to lead toxicity, biological
measurements of lead have been used to mea-
sure lead dose for decades. Indeed, the most
commonly employed of such tests, the mea-
surement of lead in whole blood, has become
one of the few human tests of an environmen-
tal toxicant that is widely available in com-
mercial U.S. laboratories and that has been
legislated as a test for monitoring exposure
required by many states (e.g., lead screening
in children) and by the federal government
[e.g., the U.S. Occupational Safety and
Health Administration (OSHA) lead standard
for workers]. 
However, a recurrent theme of this mini-
monograph is that the blood lead test cannot
be assumed to be the best and only metric of
lead exposure that matters. A blood lead level
reflects, for the most part, recent lead expo-
sure (i.e., over weeks to months) from envi-
ronmental or occupational sources. Although
lead in blood is also in equilibrium with bone
lead stores, its variability mostly reflects
changes in external exposure. Over the past
10 years or so, epidemiologic studies have
generated growing and undeniable evidence
that the most important standard for predict-
ing some adverse health outcomes is not
recent lead exposure; rather, it is cumulative
lead exposure that occurs over many years,
with or without the additional dimension of
latency (i.e., the passage of time that may be
needed for a toxic outcome to be expressed).
The concept that cumulative lead expo-
sure may be more important than recent lead
exposure derives partly from animal studies
demonstrating that the long-term administra-
tion of low doses of lead for varying lengths of
time result in animals with similar blood lead
levels but with levels of end-organ toxicity
that are directly proportional to the varying
cumulative doses [for recent examples of such
studies with respect to kidney and brain toxic-
ity, see Ghorbe et al. (2001) and Lasley and
Gilbert (2002), respectively]. The importance
of cumulative dose (and latency) has also been
supported by longitudinal epidemiologic
studies in which, compared with subjects with
low lead exposure, individuals with a clear
history of high lead exposure in the past have
been found to have a higher proﬁle of disease
despite having current blood lead levels simi-
lar to those without such a history [e.g., rates
of hypertension and adverse reproductive out-
comes (Hu et al. 1991a, 1991b), respec-
tively]. Although peak dose and timing of the
dose may also have been important to the
observed health effects in these subjects, eval-
uation of cumulative dose would not have
been possible if only current blood lead levels
had been measured.
Perhaps most important, however, has
been the development of KXRF instruments
for the in vivo measurement of lead in bone,
which provide a direct biological metric for
estimating retained cumulative lead dose in
humans (Landrigan and Todd 1994). Over
the last 12 years this development has allowed
investigators to conduct epidemiologic studies
that speciﬁcally focus on the potential adverse
health outcomes resulting from an estimate of
lifetime cumulative dose. 
Many of the studies using KXRF, includ-
ing those reviewed in this mini-monograph
concerning the toxicity of lead in adults in the
cardiovascular system and on cognitive func-
tion, have generated considerable interest in
the environmental medicine community. For
the researcher, it is as if the adverse health
effects of smoking or diabetes had always been
limited to considering how many cigarettes
per day an individual was currently smoking
or what the blood sugar level was today rather
than cumulative pack-years of smoking or the
hemoglobin A1C level, respectively. Recent
exposure, in this case, as reﬂected by the blood
lead level, remains a critically important mea-
surement, but by expanding the tool chest of
measurement methods to include measures of
cumulative dose, the ability to understand the
full expression of lead toxicity has been
markedly increased.
Lead uptake, distribution, metabolism,
and excretion. The principal routes of expo-
sure and absorption of lead are through inges-
tion and inhalation (White et al. 1998).
Absorption in the gut is partial, inﬂuenced by
physical form, chemical species of lead, and
the presence of other nutrients and dietary
cations such as iron and zinc. The molecular
mechanism for lung absorption is unknown,
but it is well known that if the physical form is
of respirable size (i.e., < 1 µm, such as lead
fume generated by burning lead paint),
absorption is efficient (> 90%; Rabinowitz
et al. 1977). Lead-containing particles
> 2.5 µm in diameter are deposited in the cili-
ated regions of the nasopharyngeal and tra-
cheobronchial airways, where they are passed
to the gastrointestinal tract by the mucociliary
lift mechanism and then subject to intestinal
absorption.
Once absorbed through either ingestion or
inhalation, lead enters the bloodstream where
it is predominantly bound to erythrocyte pro-
teins (Barltrop and Smith 1972; Bergdahl
et al. 1997; Church et al. 1993; O’Flaherty
1993; Rabinowitz 1991; Rabinowitz et al.
1976; Simons 1984, 1988), with an average
clearance half-time after a short-term limited
exposure of approximately 35 days from whole
blood (Rabinowitz 1991). Clearance occurs
through distribution into soft tissues and bone
as well as excretion, primarily through kidney
filtration and elimination in urine. A small
amount of lead is also excreted in feces, sweat,
hair, and nails.
Lead circulates widely and is found in all
organs and tissues; it also crosses the blood–
brain barrier and placenta, making the brain
and developing fetus among the targets of
concern (Hu 1998). On a molecular level,
lead binds to many proteins, especially to
thiol and carboxyl groups, and mimics cal-
cium in many biologic pathways (Goldstein
and Ar 1983; Kern et al. 2000; Rabinowitz
1991; Rabinowitz et al. 1973).
Biomarkers of lead dose. Blood lead levels,
hereafter referred to as “BLLs,” are typically
measured in whole-blood specimens that have
been collected by venous phlebotomy or by
ﬁngerstick (Schlenker et al. 1994) into tubes
containing an anticoagulant. To measure lead
concentrations in such specimens, most
Hu et al.
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absorption spectroscopy, which typically has a
limit of detection (LOD) of 1 µg/dL. Some
laboratories still use anodic stripping voltam-
metry, which has an LOD of 5 µg/dL. A
direct readout portable instrument (LeadCare
Analyzer; ESA Laboratories, Bedford, MA) is
also now available that can make measure-
ments of BLLs in the field with a LOD of
1 µg/dL. All such methods have well-standard-
ized quality assurance/quality control proce-
dures that involve the regular use of
calibration standards and participation in pro-
ﬁciency protocols.
Although the half-time of lead in blood of
35 days is widely quoted in the literature, it is
critical to appreciate that this estimate is a
reﬂection of the 120-day life span of erythro-
cytes and only applies in practice if the total
exposure is short (e.g., < 30 days). If lead
exposure is long-term (i.e., with a duration of
years), upon cessation the kinetics of clearance
of lead from blood is considerably more com-
plicated, with an initial rapid decline in levels
reflecting partial clearance from blood and
other soft tissues followed by a much slower
clearance, reﬂecting the replenishment of soft-
tissue pools of lead with lead from long-lived
deposits in bone. Thus, as a biological marker
of dose, blood lead levels can be a reﬂection of
acute external exposure, internal bone lead
stores released into blood, but, most com-
monly, a steady-state mixture of both external
exposure and internal stores with almost no
ability to distinguish between either. 
With respect to lead and bone, it has been
well established from autopsy studies that the
skeleton contains 90–95% of lead burden in
adults and 80–95% in children (Barry and
Mossman 1970; Hu et al. 1989; Schroeder
and Tipton 1968). Roughly 15% of circulat-
ing lead per day is incorporated into bone
(Rabinowitz et al. 1976), where it substitutes
for calcium in the hydroxyapatite of bone
mineral during the normal and ongoing
process of bone deposition. The bulk of lead
in bone is contained within long-lived com-
partments of cortical (clearance half-time of
decades) and trabecular (clearance half-times
of years to decades) bone, with comparatively
small amounts of lead in bone tissue compart-
ments that rapidly exchange with extracellular
ﬂuid and plasma. 
The decades-long half-time of lead in corti-
cal bone makes it a dosimeter of retained
cumulative lead dose when measured either at
autopsy, by biopsy, or by noninvasive in vivo
techniques such as KXRF. In comparison, the
much shorter half-time of lead in trabecular
bone makes it somewhat less reliable as a
dosimeter of cumulative lead dose, but it iden-
tiﬁes trabecular bone as a measure that reﬂects
a large pool of stored lead that may be more
bioavailable than cortical bone lead (Hu et al.
1998). A combination of decreased “external”
lead exposure and normal rates of bone resorp-
tion can result in bone constituting the pre-
dominant source of circulating lead in elderly
individuals (Hu et al. 1996b) or in individuals
with past long-duration high exposure and low
current exposure. There is some inconsistency
in the literature on this point. For example, in
one study of approximately 1,000 subjects
50–70 years of age with mainly environmental
lead exposure, the mean blood lead level was
approximately 4 µg/dL and the mean tibia lead
level was approximately 19 µg/g, but the
Pearson’s r correlation between the two was
only 0.12 at a time of low ongoing environ-
mental lead exposure (Martin et al. 2006;
Schafer et al. 2005). This suggests that in per-
sons whose peak lead exposures were decades
in the past, the current tibia lead is not very
bioavailable and thus does not contribute
much to current blood lead levels. Greater lev-
els of circulating lead may derive from bone
during physiologic states accompanied by
heightened bone resorption, such as pregnancy
and lactation, postmenopausal osteoporosis
(Korrick et al. 2002; Webber et al. 1995), and
hyperthyroidism (Goldman et al. 1994).
When considered in relation to a long-
term conceptual model of lead exposure,
dose, and the ability to retrospectively esti-
mate dose in individuals, it is clear that bone
lead levels provide a cumulative dose metric
that is completely distinct from that of blood
lead levels, particularly among individuals
whose peak lead exposures had occurred in
the past (Hu et al. 1998).
Except for rare circumstances, there is little
or no value in measuring lead in urine or hair.
Because of the pharmacokinetics of lead clear-
ance, urine lead changes more rapidly and
may vary independently of BLLs. Moreover,
urine lead is less validated than blood lead as a
biomarker of external exposure, or as a predic-
tor of health effects. Lead in hair, particularly
in working populations, may partially reﬂect
external contamination rather than only inter-
nal lead dose. Laboratory analysis for lead in
hair is not standardized and is highly variable
(Harkins and Susten 2003; Seidel et al. 2001).
Lead in plasma or serum (Cake et al. 1996)
has recently received attention as a biological
marker that is distinct from whole blood lead
and that by virtue of representing the fraction
of lead in blood that is most biologically avail-
able to cross cell membranes such as the pla-
centa may be better at predicting some forms
of toxicity than whole blood lead levels (Hu
et al. 2006). However, plasma or serum lead
levels are extremely low (< 1% of whole blood
lead levels); are particularly vulnerable to cont-
amination issues (including contamination
from the hemolysis of red cells, where > 99%
of lead in whole blood resides); require
extremely labor-intensive methods for their
collection, processing, quality control, and
measurement (Smith et al. 2002); and are
likely most relevant to very short-latency,
acute health effects. 
The literature on the health effects of lead
exposure also includes studies that have meas-
ured chelatable lead burden. This is measured
as lead excreted in urine collected for 4–24 hr
after administration of intravenous EDTA or
oral administration of dimercaptosuccinic acid
(DMSA) (Lee et al. 1995). In a number of
small studies, it was suggested that EDTA-
chelatable lead could be used as an estimate of
current body burden, a metric closely related
to cumulative lead dose (Sokas et al. 1988).
Other groups have thought of chelatable lead
as the bioavailable body burden (Lee et al.
1995). Although chelatable lead has been used
in large-scale epidemiologic studies, some
groups have concluded that chelatable lead
probably does not additionally contribute to
causal inference when added to studies that
have already measured blood lead and bone
lead (Dorsey et al. 2006; Weaver et al. 2005).
As such, we do not consider these metrics
further in this review.
Measurement of bone lead using KXRF.
Details regarding the measurement of lead in
bone using in vivo KXRF have been reviewed
previously (Chettle et al. 1991; Todd et al.
1992a), as has the use of bone lead in epidemio-
logic studies (Hu et al. 1989, 1998; Landrigan
and Todd 1994). Here we only brieﬂy reiterate
key points necessary to interpretation of infor-
mation in this mini-monograph. As noted
above, direct in vivo measurements of lead in
bone by KXRF have been used in epidemio-
logic research since the mid-1990s, and their
usefulness derives from their ability to provide
estimates of cumulative lead dose as well as of a
reservoir of lead that may be released into cir-
culation at high levels during periods of height-
ened bone resorption. This section contains a
brief discussion of KXRF methodology for the
nonphysicist, focusing on aspects that are of
practical value for research and clinical applica-
tions. Discussion and critiques of a second
technique, LXRF, may be found elsewhere
(Rosen and Slatkin 1993).
Most current KXRF instruments use
cadmium-109 as the low gamma radiation
source to provoke the emission of ﬂuorescent
photons from the anatomical target area (Hu
et al. 1998). The measurement is automated
and typically requires 30 min. The net lead
signal is determined after subtraction of
Compton background counts, using a nonlin-
ear, least-squares fit program (Chettle et al.
1991). The lead fluorescence signal is then
normalized to the elastic or coherently scat-
tered X-ray signal, mainly from calcium pre-
sent in bone, resulting in units of micrograms
of lead per gram of bone mineral. By normal-
izing the measurement to calcium counts, the
Methodologic issues in adult lead epidemiology
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tions in bone shape, size, density, histomor-
phometry, overlying tissue thickness, and a
small amount of movement (Somervaille et al.
1985). Radiation dosimetry studies have
demonstrated that a typical 109Cd KXRF mea-
surement gives extremely low effective dose
values of < 0.1 µSv (Todd et al. 1992b), sig-
niﬁcantly below a proposed limit of negligibil-
ity of 10 µSv (Hall 1988). Studies with
repeated measurements have indicated the
instrument provides a high degree of precision
of the point and measurement uncertainty
estimates compared with chemical analyses of
lead-doped phantoms (Aro et al. 1994) and
cadaveric legs (Aro et al. 2000). Regarding the
latter, repeated measurements of tibia bone
shown by chemical analysis to have lead con-
centrations in the 20–30 µg/g range (common
values for environmentally exposed late mid-
dle-age adults) typically demonstrate SDs of
around 3–4 µg/g (i.e., coefﬁcients of variation
of 15–20%) Studies support the inference that
a single-site bone lead measurement is repre-
sentative of total skeletal burden (Hu et al.
1990; Wittmers et al. 1988). However, several
groups have recommended separate measure-
ments of cortical and trabecular bone sites
(Chettle et al. 1991) to deal in part with
kinetic differences for lead in these compart-
ments (Kim et al. 1997). The utility of mea-
suring at cortical and trabecular sites for causal
inference in epidemiologic studies has also
been recently questioned (Dorsey et al. 2006;
Weaver et al. 2005).
Several caveats need to be noted with
respect to factors that can affect KXRF meas-
urement precision. First is that precision is
partially dependent on the mass of bone being
measured, so measurements in women and
children typically have higher measurement
uncertainties. Second, thickness of the soft tis-
sues overlying the bone being measured can
influence precision, although for midtibia
shaft this is generally not a large concern.
Precision can be affected by errors in the
placement of the instrument in relation to tar-
get bone, movement of the subject’s leg out of
the field of measurement, or curtailed meas-
urement time. Finally, it is important to note
that the quality control and assurance proce-
dures for KXRF instruments typically involve
the use of calibration standards and proce-
dures by individual laboratories. National or
international standards for the intercalibration
of KXRF instruments have not yet been estab-
lished. A process of creating intercalibration
standards, suggested intercalibration protocols,
and standard reference material consisting of
ground bone is currently under way.
Bone lead levels: interpretation and
implications. In the interpretation of bone lead
levels, a few issues must be kept in mind. First,
for low concentrations of lead in bone, in
epidemiologic studies it is recommended that
tibia lead be used as a continuous variable,
retaining all values, including those below the
LOD and those below zero (Kim et al. 1995).
Although there is some debate about the utility
of measuring cortical and trabecular sites, we
believe that if a priori hypotheses are developed
that clearly distinguish the purpose of compar-
ing different lead biomarkers, then it is reason-
able to explore the contrasting associations.
However, it must be noted that as more associ-
ations are evaluated the probability of chance
associations increases. Third, studies are
increasingly identifying how bone density
and/or bone resorption rates may influence
bone lead measurements (Goldman et al.
1994; Hu 1998; Tsaih et al. 2001), because, as
noted, bone lead contains bone mineral con-
centration in the denominator. To date, no
epidemiologic studies that have evaluated asso-
ciations of bone lead with health outcomes
have tried to control for bone mineral density
or resorption rate. Finally, it is important to
note that measures of cumulative lead dose,
such as tibia lead levels, give no information on
acute short-term “peaks” or other time-varying
aspects of lead exposure which, under certain
circumstances, may be important to appreciate
(such as documenting episodes of short-term
acute clinical lead poisoning). 
Estimating cumulative lead dose with the
CBLI. Since KXRF remains available in only
approximately seven research institutions in
North America, measurement of BLLs will
remain the mainstay of biological monitoring
for lead-exposed workers for the foreseeable
future. To address cumulative dose using the
readily available BLLs, an alternative method-
ology is to use repeated and/or estimated
measurements of blood lead over time to cal-
culate a CBLI (Somervaille et al. 1988). CBLI
is mathematically equivalent to the area under
the curve of BLLs versus time, is approxi-
mately equivalent to multiplying the average
BLL by the number of years of exposure, pro-
viding units of microgram-years per deciliter,
and is similar to what other authors have
termed the IBL index. If repeated BLLs are
available, the trapezoidal rule can be used to
compute the area under the curve to arrive at
CBLI (Appendix A). 
Validation studies comparing CBLI with
tibia lead provide evidence that CBLI is an
estimate of cumulative lead dose. Eleven sepa-
rate determinations have been made of slopes of
the relation between tibia lead and CBLI
(Armstrong et al. 1992; Cake et al. 1996;
Erkkila et al. 1992; Hu et al. 1991a; McNeill
et al. 2000; Somervaille et al. 1988). Each study
also reported sample size and the SE of the
slope, which, across the studies, ranged from
0.028 to 0.067. Although we did not perform a
formal meta-analysis, pooling of these data and
weighting by sample size provides an estimated
slope of 0.05 [95% conﬁdence interval (CI),
0.046–0.055]. These data support the notion
that CBLI and tibia lead are correlated and
the estimated slope of this relation across
studies has been remarkably consistent with a
narrow CI. In addition, this slope indicates
that tibia lead concentration (micrograms per
gram) can be estimated as 5% of the CBLI
(microgram-years per deciliter). Additional
research in this area would be useful to see if
the relationship is nonlinear, particularly
within subsets of the population, such as the
young versus the elderly. 
This knowledge allows the magnitudes of
effects to be compared across studies that have
used the two measures and for equivalences to
be estimated in the average BLL over time that
would result in a given tibia lead level. For
example, using the logistic regression model
based on data presented from the Normative
Aging Study, an increase of 29 µg/g tibia lead
(which was the increase of bone lead from the
midpoints of the lowest to highest quintiles)
would be associated with a 1.74-times increase
in the odds of hypertension regardless of the
starting bone lead level (Hu et al. 1996a). This
model predicts that a 1.5-times increase in the
odds of hypertension would be associated with
an increase in tibia lead of 21.3 µg/g, which
corresponds approximately to an increased
CBLI of 400 µg-years/dL.
A potential limitation with interpreting
CBLI and health effects is that many of the
studies that have attempted to use CBLI have
involved worker cohorts that had much
higher BLLs in the past, but lower levels at
the time data were collected and the cumula-
tive lead dose (i.e., CBLI) was calculated.
Even though not all lead-exposed workers
have had required BLL testing over time, it
may be possible to extrapolate an approxi-
mate CBLI using available BLL results along
with a careful occupational history to esti-
mate the intensity and duration of lead expo-
sure. For example, if a worker is exposed at
the current OSHA-permissible exposure limit
and permitted to have the maximum BLL
(40 µg/dL) each year for a working lifetime
(40 years), the estimated CBLI would equal
1,600 µg-years/dL, whereas a worker with a
BLL of 20 µg/dL each year for 10 years would
have a CBLI of about 200 µg-years/dL.
Another point to consider when interpret-
ing CBLI is that some of tibia lead (and blood
lead) may derive from higher past environ-
mental (nonwork) exposures. Older workers
may have higher baseline bone lead levels from
living at times when environmental exposures
were higher. The population mean BLL was
13 µg/dL in the late 1970s (Annest et al.
1983; Pirkle et al. 1994). By the late 1990s,
the mean BLL had fallen to < 3 µg/dL (Pirkle
et al. 1998). This point is relevant to cumula-
tive dose estimation with both tibia lead and
Hu et al.
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cannot clearly distinguish early from mid-life
from later life exposures using these summary
metrics and thus must interpret the critical
periods of exposure with caution. 
Thus, in this mini-monograph, we believe
that epidemiologic studies that measured
either tibia lead or CBLI have adequately esti-
mated cumulative dose. The consistent rela-
tion between tibia lead and CBLI in validation
studies clearly supports this conclusion.
Other Methodologic
Considerations
Epidemiologic research has evolved consider-
ably in its thinking about study design and
causality inference. Recent studies on lead
toxicity have been more rigorous in their con-
sideration of such important issues as selec-
tion bias, confounding, effect modification
and other forms of interactions, and complex
causal pathways. In the following sections we
brieﬂy review other issues of relevance to the
interpretation of associations in epidemiologic
studies that have relevance to the two system-
atic reviews in this mini-monograph (Navas-
Acien et al. 2007; Shih et al. 2007).
Occupational versus environmental studies.
While studies of occupationally exposed popu-
lations provided initial data about the harmful
effects of lead at high levels of exposure, envi-
ronmental studies are much less troubled by
the healthy worker effect, survivor cohorts, and
other sources of bias inherent to occupational
studies. Environmental studies also have the
capacity to encompass much larger sample sizes
with more socioeconomic and racial/ethnic
diversity than occupational studies. 
These are important differences. In some
cases, researchers conducting studies in subjects
with high chronic occupational lead exposure
have failed to observe the adverse impacts asso-
ciated with lower levels of lead in environmen-
tal settings. For example, several studies of
renal function in smelter workers have found
no evidence of clinical renal dysfunction or
changes in markers of tubular dysfunction
compared with controls (Gerhardsson et al.
1992; Omae et al. 1990; Roels et al. 1994;
Wang et al. 2002). Similarly, some occupa-
tional studies have not found signiﬁcant differ-
ences in cognitive symptoms or psychosocial
disturbances between occupationally exposed
workers and controls (Parkinson et al. 1986). 
There are many potential explanations for
null associations in occupational studies.
Occupational studies tend to be based on
small sample sizes, making them vulnerable to
type II error. Some studies had nonexposed,
or control, groups of workers with BLLs well
above current background-exposure levels
(< 5 µg/dL), which is likely to underestimate
the effect being studied. Perhaps the most
important problem is the vulnerability of
occupational studies to the healthy worker
effect, that is, the bias inherent in studying
populations of workers who remain after the
departure of sicker and/or more susceptible
workers, especially problematic in cross-
sectional studies of current workers. In studies
that compare health effects in workers with
general population controls, the healthy
worker effect could explain why associations
may not be observed, because workers are,
especially for symptomatic conditions, more
likely to be healthier than the general popula-
tion. This problem is often manifested as an
attenuation of exposure–response curves in
occupational studies at high exposure levels
(Stayner et al. 2003). If lead causes most of its
health effects at low levels, occupational stud-
ies that examine only the high end of the
dose–response range could miss associations
at the lower end or across the entire range
(Nuyts et al. 1993). It has also been reported
that there may be selection bias by δ-amino-
levulinic acid dehydratase genotype, as lead
exposure and exposure duration increase and
symptomatic workers leave the workplace
(Schwartz et al. 1995). 
Such selection bias can be mitigated in
two ways. First, although more difﬁcult, this
bias could be avoided in occupational studies
that assembled complete cohorts and ran-
domly selected workers for study, including
those who left the workplace early or late in
their careers. Of interest is that studies that
have assembled cohorts of all workers ever
employed in a given plant or industry have
reported many signiﬁcant ﬁndings not previ-
ously observed (Schwartz et al. 2000, 2001,
2005; Stewart et al. 1999). Second, longitudi-
nal studies, in comparing subjects with them-
selves in changes in health status over time,
are somewhat less susceptible to this kind of
bias, whether occupational or environment.
Community-based studies of the general
population avoid the healthy worker effect
entirely, making them an especially important
study design, although a similar form of bias
can be encountered in studies limited to just
older subjects in the general population. 
In this mini-monograph, both occupa-
tional and environmental studies were chosen
for inclusion in the systematic reviews (Navas-
Acien et al. 2007; Shih et al. 2007). When
evaluating the associations of cumulative lead
dose with health outcomes, investigators need
to acknowledge that nonoccupational sources
of lead exposure were present for all members
of the general population in the United
States, including lead workers, throughout
most of the 20th century until public health
interventions progressively removed lead from
gasoline and many consumer products during
the 1970s and 1980s (Agency for Toxic
Substances and Disease Registry 1999; Annest
et al. 1983; Pirkle et al. 1998). Lead remains a
low-level and ubiquitous neurotoxicant in the
environment and is found in measurable lev-
els in all individuals (Hoppin et al. 1995).
Thus, current tibia lead levels may represent a
mix of environmental exposures and potential
occupational exposures. 
Race/ethnicity, socioeconomic status, and
other factors/covariates. Environmental lead
exposure differs by race/ethnicity and socio-
economic status. Persons with low socio-
economic status (e.g., educational attainment,
income, assets) have been known to have
higher blood lead levels throughout at least the
period of the recurrent National Health and
Nutrition Examination Survey (NHANES)
blood lead surveys (Annest et al. 1983; Elreedy
et al. 1999; Pirkle et al. 1998). Several investi-
gators have also reported higher bone lead
levels in minorities compared with whites.
For example, Martin et al. (2006) recently
reported that tibia lead levels among a popula-
tion-based sample of individuals 50–70 years
of age in Baltimore, Maryland, were 30%
higher in African Americans than in whites
(Martin et al. 2006). Lin et al. (2004) reported
higher tibia and patella lead levels in minori-
ties compared with predominantly white sub-
jects who were older than 55 years and living
in Boston, Massachusetts (Lin et al. 2004).
One study reported higher tibia and patella
lead levels in blue-collar workers compared
with white-collar workers and this association
was modiﬁed by race/ethnicity (Elmarsafawy
et al. 2002). 
The strong associations of cumulative lead
dose with race/ethnicity and socioeconomic
status raises methodologic concerns. Factors
that in the past were simply termed “con-
founding variables” are now more carefully
evaluated as potential mediators (i.e., in the
biological causal pathway), moderators (i.e.,
risk modifiers), direct causes, or otherwise
parts of complex causal pathways (Kraemer
et al. 2001). It is now understood that such
complex causal pathways also apply to lead
exposure and chronic disease, including cog-
nitive dysfunction, hypertension, and renal
dysfunction. These pathways can include con-
nections between individual-level indicators
(e.g., age, sex, race/ethnicity, socioeconomic
status); behavioral risk factors; biological fac-
tors (e.g., genetics); social factors (e.g., social
capital, social cohesion); lead dose (i.e., both
recent and cumulative); health conditions
(e.g., diabetes, heart disease, hypertension);
and other biological markers predictive of dis-
ease (e.g., homocysteine levels) that may be
thought of as either outcomes by themselves
or as intermediate pathological states that
result in other conditions (e.g., renal dysfunc-
tion, cognitive declines). 
What are the implications of the fact that
race/ethnicity and socioeconomic status may
be causally related to cumulative lead dose?
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ated with higher BLLs in population-based
surveys, early life lead exposure has been
shown to cause intellectual impairment and
worse educational outcomes (Banks et al.
1997; Canﬁeld et al. 2003; Needleman et al.
1979, 1996, 2002; Pocock et al. 1994), which
in turn may influence socioeconomic status
attainment in later life. Thus, although early
studies of lead and cognitive function argued
that controlling for education was an impor-
tant necessity, when including the contribu-
tion of early life lead exposures, the potential
reciprocal causation may lead to an underesti-
mation of the association between lead dose
and cognitive function if education is
included in regression models. This has also
been recently discussed in the context of lead
and blood pressure (Martin et al. 2006). 
A similar issue has been raised concerning
race/ethnicity. To the extent that race/ethnic-
ity serves as a proxy for other factors influ-
enced by early lead exposure and also
adversely affect cognitive function or cardio-
vascular outcomes (Navas-Acien et al. 2007;
Shih et al. 2007), adjusting for race/ethnicity
could underestimate the overall effect of that
early lead exposure. Some authors have thus
argued that there should not be adjustment
for race/ethnicity (Martin et al. 2006; Shih
et al. 2006). If later life lead exposure also
affects the measured cognitive or cardiovascu-
lar outcome, then to the extent that race/eth-
nicity also serves as a proxy for factors that
influence later life lead exposure and these
outcomes, not adjusting for race/ethnicity
may introduce bias. 
Thus, it can be concluded that inclusion
of race/ethnicity in models evaluating rela-
tions of cumulative lead dose and cognitive
function or cardiovascular outcomes could
lead to an underestimation of the direct effect
of lead. Given these complex causal pathways,
we believe relations of tibia lead and these
outcomes are likely to be best estimated by
parsimonious regression models that control
for such variables as age, sex, and testing tech-
nician, for example, but not necessarily those
that include race/ethnicity and socioeconomic
status, which is at odds with what has been
concluded by other authors (Goodman et al.
2002; Lindgren et al. 1996) and with our ear-
lier thinking on this issue (Balbus-Kornfeld
et al. 1995). It may be most informative in
the future if analyses were explicitly reported
(and appropriately interpreted) that both
included and excluded race/ethnicity and
measures of socioeconomic status. 
The ideal solution to such a conundrum,
although not often possible, would be to have
separate measures of early-life and late-life
lead exposures and/or direct measures of the
underlying factors for which race/ethnicity is
serving as a proxy (LaVeist 1994) and possibly
applying statistical methods such as marginal
structural models to account for variables that
are both mediators in the pathway to expo-
sures and confounders of later exposures
(Robins et al. 2000). Another issue of concern
when considering race/ethnicity is that there
might be plausible physiologic differences by
race/ethnicity that affect the association
between lead and cognitive or cardiovascular
outcomes. In such a case, one must consider
effect modiﬁcation by race/ethnicity in analy-
ses, although not without the same considera-
tions raised above regarding the precise factors
for which race/ethnicity is serving as a proxy
(LaVeist 1994). Although stratiﬁed analysis by
race/ethnicity is one approach to these con-
cerns, very few epidemiologic studies are
designed to be adequately powered for strati-
ﬁed analysis, and thus loss of statistical signiﬁ-
cance is often the result. Stratified analysis
should not be necessary if evaluation of effect
modiﬁcation in a single model (i.e., by inclu-
sion of an interaction term between lead dose
and race/ethnicity) reveals no evidence that
the association with lead dose differs by
race/ethnicity.
A number of important individual-level fac-
tors, in addition to race/ethnicity and socio-
economic status, are frequently considered in
Hu et al.
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Appendix A. Calculation of Cumulative Blood Lead Index.
CBLI gives a useful summary of a set of sequential blood lead measure-
ments from individuals. For example, how could the following data
from an individual followed over time from 1996 be summarized?
No. Date Blood lead (µg/dL)
1. 1 June 1997 6.0
2. 1 June 2001 1.0
3. 1 June 2004 1.0
To calculate the CBLI using the Trapezoidal Rule, take a piece of
graph paper and draw a set of axes, the horizontal axis representing
time, the vertical axis representing blood lead concentration. Label the
ﬁrst time point after the origin on the horizontal axis with the date of
the first available blood lead test. Label the vertical blood lead axis
with the range of expected blood concentration. Draw a dot represent-
ing the coordinates (time and lead concentration) of the three meas-
urements. Connect the dots with straight lines.
Draw a horizontal line across the plot at blood lead = 0. From
each dot draw a vertical line to the zero blood lead line. Draw hori-
zontal lines connecting each vertical line so that a triangle and a rec-
tangle are formed between each adjacent pair of data points.
Measure the height in units of lead and the width in units of time
of each triangle and rectangle in the plot and record them on the
appropriate parts of the triangles and rectangles.
Use the formula for area of a triangle and area of a rectangle to
calculate the area of each triangle and rectangle drawn:
Area of triangle = (base × height)/2
Area of rectangle = (base × height)
The ﬁrst time interval in the data set, 1 June 1997 to 1 June 2001, is
4 years. The sum of the heights of the stacked triangle and rectangle
(trapezoid) of the ﬁrst data point is 6 µg/dL, with the height of the trian-
gle being 5 µg/dL and the height of the rectangle below it 1 µg/dL. The
area of the triangle of the ﬁrst interval is (5 × 4)/2 = 10 µg-years/dL; the
area of the rectangle below it is 4 × 1 = 4 µg-years/dL. Write each area
inside the triangle or rectangle. 
The sum of the area of the triangle and the rectangle gives the total
CBLI of the patient between 1997 and 2001 (10 + 4 = 14 µg-years/dL). 
Move on to the next time interval, 1 June 2001 to 1 June 2004.
Repeat the drawing of the triangle and the rectangle. In this interval
the blood lead concentration remained the same, so draw only a rec-
tangle. The height of this rectangle is 1 µg/dL and the length is
3 years. The area of this rectangle is 1 × 3 = 3 µg-years/dL, which is
also the value of the CBLI for the 3-year interval. Write the area
inside the rectangle.
To calculate the total CBLI, add the CBLI values previously cal-
culated as areas. In this example, the CBLI for the ﬁrst interval was
14 µg-years/dL and for the second interval was 3 µg-years/dL, so the
total CBLI for the interval between 1 June 1997 and 1 June 2004 is
17 µg-years/dL. 
The Trapezoidal Rule method of calculating CBLI will slightly
overestimate CBLI for subjects with suddenly decreased exposure and
will slightly underestimate CBLI for subjects with lead exposure that
is seasonal or occasional, depending on the blood sampling interval.
Better accuracy is assured by shorter sampling intervals, at least every
6 months. Longer sampling intervals may be used for subjects with
unchanging exposure, although with some loss of accuracy.Methodologic issues in adult lead epidemiology
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the body of literature on the health effects of
lead. When comparing associations of health
outcomes with blood and bone biomarkers, it is
essential to recognize that factors such as age,
sex, and elevated bone turnover accompanying
osteoporosis (Silbergeld et al. 1988; Webber
et al. 1995) may modify lead toxicokinetics.
These factors may co-vary with age, race/
ethnicity, and sex, and genetic polymorphisms,
complicating consideration of these issues. 
An increasing body of evidence suggests
that lead is associated with a number of health
conditions that are also causes of cognitive
decline, including hypertension (Hertz-
Picciotto and Croft 1993; Hu et al. 1996a;
Nash et al. 2003; Sharp et al. 1987), elevated
homocysteine levels (Schafer et al. 2005), and
psychiatric symptoms (Rhodes et al. 2003;
Schwartz et al. 2001). Each of these health
conditions may mediate or moderate (or con-
found, in the absence of temporality) relations
between lead dose and cognitive function. 
Two important health behaviors—
tobacco and alcohol consumption—have
been linked with risk of cardiovascular and
cognitive outcomes. This begs the question of
whether it is critical to adjust for tobacco and
alcohol consumption in evaluating relations
of lead dose with cardiovascular and cognitive
outcomes. The numerous studies of tobacco
and alcohol consumption and its relations
with cognitive function are conflicting
(Carmelli et al. 1999; Cervilla et al. 2000;
Crawford et al. 2001; Elias et al. 1999;
Elwood et al. 1999; Hendrie et al. 1996;
Schinka et al. 2002, 2003). We do not believe
that control for these variables is absolutely
necessary and can be guided by modeling and
appropriate interpretation of causal pathways. 
As another example, smoking is often
included in models of hypertension, and its
impact on blood pressure remains an impor-
tant potential mechanism for its status as a risk
factor for end-organ dysfunction (Orth 2004).
Tobacco is well known to have been contami-
nated by lead arsenate pesticide in the past and
smoking has been identiﬁed as a risk factor for
increased cumulative lead burden (Hu et al.
1996b). Thus, it is possible that epidemiologic
studies of hypertension that adjust for smok-
ing are “over-controlling” for a risk factor
(smoking) that is associated with the exposure
of interest (lead), underestimating the direct
effect of lead. Similar concerns pertain to alco-
hol, which has been linked to the pathogenesis
of hypertension [with moderate to heavy con-
sumption (Beilin and Puddey 2006)] and is
also well-known risk factor for elevated lead
exposure (Lee et al. 2005). 
Conclusions
Two articles in this mini-monograph (Navas-
Acien et al. 2007; Shih et al. 2007) are sys-
tematic reviews of studies that have examined
associations of lead dose with cognitive and
with cardiovascular outcomes. For the reasons
reviewed in this article, both reviews focus on
studies that measured both recent dose,
mainly with blood lead, and cumulative dose,
mainly with tibia lead, but also with trabecular
bone lead and CBLI. By comparing and con-
trasting associations of blood lead with those
using a cumulative dose metric, studies can
attempt to distinguish the acute effects of
recent dose from the chronic effects of cumu-
lative dose. Although, for the reasons reviewed
above, comparison of associations with these
different biomarkers does not allow absolute
differentiation of these different effects, studies
that have compared associations can more
readily generate hypotheses about how lead
inﬂuences health, which dose period is more
important, and whether health effects are
more likely to be reversible or irreversible. 
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